ACE2 and intrahepatic cholangiocarcinoma: Interestingly, the group of Other ImSupp patients present with significantly lower the Spike/ACE2-blocking antibodies and levels of N-IgG at >90 days, whereas the levels of Spike IgG were not significantly different to ICC and SOT patients (Figure 2B).